Medeon Biodesign (6499) — Cash Flow Quality Index

Latest as of March 2022: 0.90x

Medeon Biodesign (6499) has a Cash Flow Quality Index of 0.90x as of March 2022. Operating cash flow of NT$60.74 Million is below net income of NT$67.17 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Medeon Biodesign cash flow conversion to assess how effectively this company generates cash.

Cash Flow Quality Index

0.90x
Operating CF / Net Income

Operating Cash Flow

NT$60.74 Million
TWD

Net Income

NT$67.17 Million
TWD

Data as of

Mar 2022
Most recent filing

Medeon Biodesign Cash Flow Quality Index (2018–2021)

Historical Cash Flow Quality Index for Medeon Biodesign across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Medeon Biodesign (6499) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for Medeon Biodesign (2018–2021)

Year-by-year earnings quality comparison for Medeon Biodesign. For live market cap and the full company financial profile, see Medeon Biodesign stock valuation.

Year Quality Index Operating CF (TWD) Net Income YoY Change
2021 -0.14x NT$-293.38 Million NT$2.08 Billion ▼ -111.2%
2018 1.26x NT$322.05 Million NT$256.60 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.